Navepegritide Patent Expiration

Navepegritide was first introduced by Ascendis Pharma Growth Disorders As in its drug Yuviwel on Feb 27, 2026.

Navepegritide Patents

Given below is the list of patents protecting Navepegritide, along with the drug name that holds that patent and the company name owning that drug.

Filter patents by

^NEW

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Yuviwel	US12377133	Dry Pharmaceutical Formulations Of Cnp Conjugates	Nov 12, 2042	Ascendis
Yuviwel	US10835578	Cnp Prodrugs With Large Carrier Moieties	Jan 05, 2037	Ascendis
Yuviwel	US11154593	Cnp Prodrugs With Large Carrier Moieties	Jan 05, 2037	Ascendis
Yuviwel	US11224661	Controlled-Release Cnp Agonists With Increased Nep Stability	Jan 05, 2037	Ascendis
Yuviwel	US11311604	Controlled-Release Cnp Agonists With Low Npr-C Binding	Jan 05, 2037	Ascendis
Yuviwel	US11389510	Controlled-Release Cnp Agonists With Low Initial Npr-B Activity	Jan 05, 2037	Ascendis
Yuviwel	US11389511	Controlled-Release Cnp Agonists With Reduced Side-Effects	Jan 05, 2037	Ascendis
Yuviwel	US11413351	Cnp Prodrugs With Carrier Attachment At The Ring Moiety	Jan 05, 2037	Ascendis
Yuviwel	US12083182	Controlled-Release Cnp Agonists With Increased Nep Stability	Jan 05, 2037	Ascendis
Yuviwel	US12156917	Cnp Prodrugs With Carrier Attachment At The Ring Moiety	Jan 05, 2037	Ascendis
Yuviwel	US12239689	Controlled-Release Cnp Agonists With Low Initial Npr-B Activity	Jan 05, 2037	Ascendis
Yuviwel	US8906847	Prodrug comprising a drug linker conjugate	Apr 30, 2031	Ascendis

Drugs Generating Over $1 Billion in Annual Revenue

Explore the top-performing drugs that dominate the pharmaceutical industry

View List

NCE-1 Patent Expiry in the Next 1 Year

Identify opportunities as new chemical entity (NCE-1) patents approach expiry

View List

Recently Granted Patents in EP

Find the opportunity to file Oppositions

View List